Member Info for Wigwammer

Seems the MM’s are maintaining an entirely false market in these shares. At the reported bid and ask, you can buy large quantities of stock, but cannot sell even the smallest amount. This really shouldn’t be allowed to go on. Who is supplying the market with shares? Is it a person with managerial and thus inside status? If so, why are the sells not reported? Leaves a very poor taste.

Yes. Shocking that a stock with a full LSE listing is allowed to move in this way. No visibility to understand such violent swings, little reported volume, no word from management, no purchases from management… really shoddy :(

Chief Executive Officer, Neil Martin, was paid £628k by RM last year, yet he has not made a single share purchase in the business since the stock plummeted last month. Given the absolute farce going on, the least he could do is put some of that money where his mouth is. IMO

Well at least some of the froth has been blown away (judging by some of the wet blankets on here). Might now get a decent reaction IF the news is positive. ATB

Oh. So It seems the options and other dilutions ARE relevant after all… worra surprise :)

Unfortunately, the FDA and not Avion decide which drugs get approved, and they haven’t seen enough evidence yet. 5+ upticks suggests a lot of hot air already built into price, one wonders whether trial approval will be a damp squib :(

Lol maestro. Unfortunately the FDA require more than TM’s speel as proof that Lupuzor works :)

“The drug works” says maestro1. Erm - think they need to prove that in a ph3 trial first :)

Fair point nolupus. Not clear how they will pay for CIDP trial yet, remains unfunded. So either partner or more dilution I guess.

That’s right, nolupus. And the £250m valuation was based on 100% ownership, and the chance of vastly higher upside in the event they got a successful result and approved product. GLA

I’m afraid the upside potential you describe is a small fraction of what is was last time, when they had 100% ownership. So expecting the valuation to hit £250m again appears spurious. But very best of luck :)

Imm WAS fully funded and owned 100% of the rights to US Lupuzor, when the market cap hit £250m. Now, the trial is being funded by Avion, and in exchange, IMM has handed over the majority of ownership to US Lupuzor to them. Obviously, when such a large part of the potential upside has been handed to someone else, you cannot expect to see the same valuation. GLA

When IMM was valued at £250m during the last phase 3, it was fully funded and owned 100% of the rights to Lupuzor in the US. This time, they have paid for the ph3 trial by handing over most of the ownership of Lupuzor in the US to Avion. So it is unlikely to hit the same valuation again, because they have already handed over a highly material part of the upside. ATB

Hopefully yes, the punt pays off. At which point the dilutions start kicking in. GLA

“warrants are good for companies in the main”…lambo is evidently a little wet behind the ears.. bless :)

Panda - Nolupus identified around 150m in options/warrants/other potential dilutions. Probably about right. That’s a dilution of around 47% of the currently listed shares. So yes, by any appropriate use of the term -it is “shed loads”. But even assuming fully diluted 475m shares in issue, it still means market cap is £28.5m. Pretty cheap for a company with a fully funded ph3 in a big indication (just not as cheap as some of the ramp crew suggest)… ATB

If nolupus has been giving cautionary postings over recent years, well done him. It’s been a dog. At least he got the risk part right, and if he held a position then did so with his eyes open.

Quite right, nolupus.. “ Wigwammer.. you are right to look at both sides of the coin here , no matter what lambo says …Eyes to the sky but feet on the ground :-)”

I will post what I want, when I want. Thank you. If you do not wish to read it, use the filter function. ATB

Well cuvio, you stated in your previous post that full dilution should be shown in an investor presentation, now you are stating that you do not concede that options/warrants - a key part of a FD calculation - is a matter for an investor presentation. Perhaps another typo, like the 325M fully diluted figure you stated. ATB